Roche Unveils New Analytical Units For Cobas pro Integrated Solutions

Roche, a leading biotechnology firm, declared the availability of its new analytical units, the cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in nations accepting the CE mark. The cobas c 703 and cobas ISE neo logical units offer state of the art features to help address some of of the key difficulties faced by diagnostic laboratories worldwide comprises lack of qualified staff and space limitations.   

“Today more than ever, accurate and timely diagnostics is critical for effective delivery of healthcare. Labs are under increasing pressure to process more samples, at greater speed without compromising on accuracy,” said Matt Sause, CEO of Roche Diagnostics. “With the launch of the cobas c 703 and cobas ISE neo, we are taking our latest generation clinical chemistry and immunochemistry platform, the cobas pro integrated solutions, to the next level. By integrating high-volume clinical chemistry testing and increased automation, we will set a new standard for high volume testing in the clinical lab.”

The new cobas c 703 insightful unit is intended to twofold the clinical chemistry throughput on cobas pro integrated solutions, presenting to 2,000 tests each hour and 70 reagent positions. With more onboard reagent capacity, more high-value tests can be run, workflow efficiency is improved, and reagent reloading time is reduced. This new unit will limit operator maintenance to one time each month, expanding uptime for laboratories.